Cefamandole nafate therapy of respiratory tract, skin, and soft tissue infections in 74 patients.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D002435:Cefamandole / Q000009:adverse effects / Q000627:therapeutic use*; D002481:Cellulitis / Q000188:drug therapy*; D002511:Cephalosporins / Q000627:therapeutic use*; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D013293:Enterococcus faecalis; D006192:Haemophilus Infections / Q000188:drug therapy; D006801:Humans; D011008:Pneumococcal Infections / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D012874:Skin Diseases, Infectious / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D013297:Streptococcus pyogenes
D002511:Cephalosporins; D002435:Cefamandole